Canada Markets open in 2 hrs 22 mins

Medexus Pharmaceuticals Inc. (MEDXF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
2.0450-0.0024 (-0.12%)
At close: 12:43PM EDT
Sign in to post a message.
  • N
    Napco
    Conditioning with treosulfan and fludarabine (Treo/Flu) has been proven to be feasible and efficient in several types of malignancies https://www.newswise.com/articles/treosulfan-plus-fludarabine-versus-team-as-conditioning-treatment-before-autologous-nbsp-stem-cell-nbsp-transplantation-for-b-cell-non-hodgkin-lymphoma?ta=home
  • N
    Napco
    Does this mean medac will respond before or on July on the latest FDA request?
    medac received acknowledgement of receipt from the U.S. Food and Drug Administration (FDA) of the New Drug Application resubmission for Treosulfan (NDA) submitted on April 21, 2022, together with a request to submit information in order to complete medac’s NDA resubmission and initiate FDA review. The FDA requested certain updates to data files submitted by medac and certain supporting information relating to data provided by medac. medac expects to respond to the FDA’s information requests within the 12-month timeline required by the FDA’s July 2021 Complete Response Letter. The review clock for the NDA resubmission will start after the response is considered complete by the FDA.
  • R
    Rita
    Any news? is trading halted?
  • Y
    Yahoo Finance Insights
    MDP.TO is down 5.00% to 2.85
  • Y
    Yahoo Finance Insights
    MDP.TO is down 5.06% to 3.00
  • R
    Ryan
    Medexus Pharmaceuticals Announces Clear Path to FDA Decision Following medac’s Type A Meeting with FDA on Treosulfan
    www.medexus.com
  • L
    Logan
    Record revenue of 31.5M and net loss now just at 0.5M. This is a no brainer Pharma play
  • R
    Ryan
    Thanks for the cheap shares
  • A
    Amin
    This company announced very good news a few days ago. I don't understand the reason behind this price action.
  • R
    Roderick
    So Nasdaq listing? where is it? lol
  • B
    Benjamin
    Looking forward to seeing the uplist onto nasdaq. Hopefully we will see the price move higher then. Great little company
  • K
    Khan
    1B Market Cap by 2022, book it. ~$40/share
  • L
    Logan
    Just started my entry ! This company looks promising
  • D
    Dex
    been holding this a while - thought if the got FDA approval it would have accelerated up but looks like a delay with FDA Im optimistic this will happen - the market treated MDP like a BioTech company which we are not lol
    it's not like a drug failed a clinical study or huge side effects were prevalent. This same drug is approved in Canada and EU so just a matter of time
  • G
    Gerald
    Please tell me this has a US ticker
  • P
    Phil
    It's uncanny how Canadian "growth" stocks can only ever sustain one leg up before crashing back down.
  • C
    Christina
    I'd recommend people start doing a search through Global Newswire with their stock ticker to read press releases.

    They have quite a few promising drugs in Canada and the US. And several in their pipeline. They just announced expanding availability of Gleolan in Canada, a fluorescent that assists neurosurgeons in the visualization of malignant tissue during surgery in patients with Grades III or IV gliomas.

    In my opinion, Canada is going to be a very dominant player in the pharma market. Their government is aggressively funding drug research and they've gone as far as to start piloting BioNano Saphyr (BNGO) units in some of their hospitals; it is by far the cheapest, most accurate, and most advanced whole-genome mapping device in the industry. The unit is also being used at the Mayo, John Hopkins, and MD Anderson for cancer research.
  • C
    Christina
    Fantastic long term buy. I plan on loading up on more soon.
  • A
    Alex
    Nasdaq delayed...
    At least we will get to the TSX which is a good step that should get the volume up